Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year
EXHIBIT 99.1 Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook ORANGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial results for its third quarter ended Sept. 30, 2026.
“Our third-quarter membership and revenue growth demonstrate continued demand for Alignment’s products and services, while medical trends ran higher than expected,” said John Kao, chairman and CEO. “We are taking a prudent approach to the fourth quarter and lowering our outlook based on current headwinds. Our revised guidance does not assume any benefit from the actions underway. We are confident we can deliver against these expectations. Our focus now is on execution and taking the steps necessary to drive more consistent performance as we scale and deliver profitable growth over the long term.”
Third Quarter 2026 Financial Highlights All comparisons, unless otherwise noted, are to the three months endedSeptember 30, 2025.
* Please see “Third Quarter 2026 Non-GAAP Reconciliation Tables” below for more information on the non-GAAP financial measures reported here as supplemental information.
Outlook for Fourth Quarter and Fiscal Year 2026 Full-year health plan membership and revenue guidance was raised to reflect continued sales momentum, while adjusted gross profit and adjusted EBITDA guidance was lowered to reflect higher medical costs experienced during the third quarter.
Three Months Twelve Months Ending Ending December 31, 2026 December 31, 2026 ────────────────────────────────────────────────────────────────────────────── $ Millions No Less Than No Less Than Health Plan 305,000 305,000 Membership Revenue $1,316 $5,245 Adjusted Gross $104 $575 Profit(1) Adjusted $(28) $100 EBITDA(1) Adjusted gross profit and adjusted EBITDA are non-GAAP financial measures presented as supplemental disclosure. We cannot provide estimated ranges for the most directly comparable GAAP measures without unreasonable efforts because of the uncertainty (1) around certain items that may impact such GAAP measures, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted. See “Third Quarter 2026 Non-GAAP Reconciliation Tables” for additional information.
Thr… Nine Mon… Mont… End… Ended (d… Sep… Sept… in 30, 30, th… 2026 2025 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net in… $ (8,0… ) $ 3,7… $ 39,… $ 10,0… (l… Le… Net lo… at… — — — (254 ) to no… in… Ad… Inte… 4,280 3,9… 12,… 11,8… expe… Depr… and 8,115 7,9… 23,… 22,6… amor… Inco… tax (22 ) 2 1,2… 3,247 expe… Equi… 17,4… 16,… 49,… 48,9… comp… Liti… — 546 481 1,608 cost… Gain on sale of — — (1 ) (72 ) prop… and equi… Ad… $ 21,8… $ 32,… $ 127… $ 98,5… EB… Adju… EBIT… is a non-… fina… meas… that is pres… as supp… disc… that we defi… as net inco… (los… befo… inte… (1) expe… inco… taxe… depr… and amor… expe… cert… liti… cost… gains or loss… on sale of prop… and equi… and equi… comp… expe… Amor… expe… for the nine mont… ended Sept… 30, 2025 incl… $0.6 mill… in impa… expe… rela… to the reme… (2) of good… asso… with one of our subs… There was no impa… expe… for the three mont… ended Sept… 30, 2025. Repr… equi… comp… rela… to (3) gran… made in the appl… year. Repr… liti… costs cons… outs… of the ordi… cour… of busi… based on the foll… cons… which we asse… regu… (i) the freq… of simi… cases that have been brou… to date, or (4) are expe… to be brou… with… two year… (ii) comp… of the case, (iii) natu… of the reme… soug… (iv) liti… post… of the Comp… (v) coun… invo… and (vi) the Comp… over… liti… stra…
Conference Call Details The company will host a conference call at 5 p.m. EDT today to discuss these results and management’s outlook for future financial and operational performance. A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: . A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web links, and will remain available for approximately 12 months.
About Alignment Health Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit .
Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the quarter and year ending Dec. 31, 2026. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully execute our business plan and achieve anticipated operational improvements and financial results; our ability to manage changes in medical costs and healthcare utilization, and our ability to accurately estimate, price for and manage such costs and utilization; our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to achieve and maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor, including potential federal reductions in MA funding; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.
Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) September 30, December 31, (Unaudited) 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets: Cash and cash equivalents $ 727,694 $ 575,817 Accounts receivable (less allowance for credit losses of 242,545 253,207 $699 at September 30, 2026 and $833 at December 31, 2025) Investments - current 15,260 28,413 Prepaid expenses and other current 192,808 94,140 assets Total current assets 1,178,307 951,577 Property and equipment, net 66,439 64,251 Right of use asset, net 7,206 7,019 Goodwill 32,060 32,060 Intangible assets, net 4,550 4,550 Other assets 8,301 6,329 Total assets $ 1,296,863 $ 1,065,786 Liabilities and Stockholders' Equity Current Liabilities: Medical expenses payable $ 621,746 $ 474,569 Accounts payable and accrued 34,562 33,284 expenses Accrued compensation 32,744 49,013 Total current liabilities 689,052 556,866 Long-term debt, net of debt issuance 324,497 323,176 costs Long-term portion of lease 6,202 6,467 liabilities Total liabilities 1,019,751 886,509 Stockholders' Equity: Preferred stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2026 and December — — 31, 2025, respectively; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock, $0.001 par value; 1,000,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 209,152,387 and 209 205 204,153,619 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 1,245,996 1,188,089 Accumulated deficit (969,093 ) (1,009,017 ) Total stockholders' equity 277,112 179,277 Total liabilities and stockholders' $ 1,296,863 $ 1,065,786 equity
Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) Nine Months Ended Operating September 30, Activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 39,924 $ 10,028 Adjustments to reconcile net income to net cash provided by operating activities: Provision for credit 699 548 loss Gain on sale of property and (1 ) (72 ) equipment Depreciation and 23,834 22,648 amortization Amortization-invest… (478 ) (1,041 ) discount Amortization-debt 1,790 1,321 issuance costs Equity-based 49,680 48,967 compensation Non-cash lease 1,439 1,178 expense Changes in operating assets and liabilities: Accounts receivable 9,963 (66,451 ) Prepaid expenses and other current (98,668 ) (84,326 ) assets Other assets (9 ) (47 ) Medical expenses 147,177 239,008 payable Accounts payable and 1,004 11,185 accrued expenses Accrued compensation (16,269 ) 8,349 Lease liabilities (1,690 ) (993 ) Net cash provided by operating 158,395 190,302 activities Investing Activities: Purchase of (32,510 ) (45,194 ) investments Sale of property and — 75 equipment Maturities of 46,135 57,995 investments Sale of business — 1,065 Acquisition of property and (25,952 ) (21,752 ) equipment Net cash used in (12,327 ) (7,811 ) investing activities Financing Activities: Debt issuance costs (2,397 ) (26 ) Proceeds from stock 8,231 2,771 option exercises Net cash provided by financing 5,834 2,745 activities Net increase in cash 151,902 185,236 Cash, cash equivalents and restricted 577,937 434,942 cash at beginning of period Cash, cash equivalents and restricted $ 729,839 $ 620,178 cash at end of period Supplemental disclosure of cash flow information: Cash paid for $ 7,013 $ 6,740 interest Supplemental non-cash investing and financing activities: Acquisition of property in accounts $ 9 $ 79 payable
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total above:
Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio, Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that our management uses to assess our operating performance. Because these measures facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.
Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.
Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net income (loss), which is the most directly comparable financial measure calculated in accordance with GAAP.
Our use of the term Adjusted EBITDA may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.
We calculate our MBR by dividing total medical expenses, excluding depreciation, and medical equity-based compensation, by total revenues in a given period.
Adjusted gross profit is a non-GAAP financial measure that we define as income (loss) from operations before depreciation and amortization, medical equity- based compensation expense, and selling, general, and administrative expenses.
Adjusted gross profit should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted gross profit in lieu of income (loss) from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.
Our use of the term adjusted gross profit may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.
Full text with the tables
EXHIBIT 99.1
Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year
Outlook
ORANGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc.
(NASDAQ: ALHC), today reported financial results for its third quarter ended
Sept. 30, 2026.
“Our third-quarter membership and revenue growth demonstrate continued demand
for Alignment’s products and services, while medical trends ran higher than
expected,” said John Kao, chairman and CEO. “We are taking a prudent approach to
the fourth quarter and lowering our outlook based on current headwinds. Our
revised guidance does not assume any benefit from the actions underway. We are
confident we can deliver against these expectations. Our focus now is on
execution and taking the steps necessary to drive more consistent performance as
we scale and deliver profitable growth over the long term.”
Third Quarter 2026 Financial Highlights
All comparisons, unless otherwise noted, are to the three months endedSeptember
30, 2025.
* Please see “Third Quarter 2026 Non-GAAP Reconciliation Tables” below for more
information on the non-GAAP financial measures reported here as supplemental
information.
Outlook for Fourth Quarter and Fiscal Year 2026
Full-year health plan membership and revenue guidance was raised to reflect
continued sales momentum, while adjusted gross profit and adjusted EBITDA
guidance was lowered to reflect higher medical costs experienced during the
third quarter.
Three Months Twelve Months
Ending Ending
December 31, 2026 December 31, 2026
──────────────────────────────────────────────────────────────────────────────
$ Millions No Less Than No Less Than
Health Plan 305,000 305,000
Membership
Revenue $1,316 $5,245
Adjusted Gross $104 $575
Profit(1)
Adjusted $(28) $100
EBITDA(1)
Adjusted gross
profit and
adjusted EBITDA
are non-GAAP
financial
measures
presented as
supplemental
disclosure. We
cannot provide
estimated ranges
for the most
directly
comparable GAAP
measures without
unreasonable
efforts because
of the
uncertainty
(1) around certain
items that may
impact such GAAP
measures,
including
equity-based
compensation
expense and
depreciation and
amortization,
that are not
within our
control or cannot
be reasonably
predicted. See
“Third Quarter
2026 Non-GAAP
Reconciliation
Tables” for
additional
information.
Third Quarter 2026 Non-GAAP Reconciliation Tables
Adjusted Gross Profit is reconciled as follows:
Three Nine
Mont… Months
Ended Ended
(do… Sept… Septe…
in 30, 30,
tho… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Inc…
(lo… $ (3,7… ) $ 7,681 $ 53,8… $ 25,036
from
ope…
Add
bac…
Equi…
comp… 1,511 1,775 4,815 4,521
(med…
expe…
Depr…
(med… 7 8 33 74
expe…
Depr…
and 8,108 7,977 23,8… 22,574
amor…
Sell…
gene…
and 136,… 110,… 388,… 317,6…
admi…
expe…
Total
add 145,… 119,… 417,… 344,8…
back
Adj…
gro… $ 142,… $ 127,… $ 470,… $ 369,8…
pro…
Adju…
gross
prof…
is a
non-…
fina…
meas…
that
is
pres…
as
supp…
disc…
that
we
defi…
as
(1) inco…
(los…
from
oper…
befo…
depr…
and
amor…
medi…
equi…
comp…
expe…
and
sell…
gene…
and
admi…
expe…
Amor…
expe…
for
the
nine
mont…
ended
Sept…
30,
2025,
incl…
$0.6
mill…
in
impa…
expe…
rela…
to
the
reme…
(2) of
good…
asso…
with
one
of
our
subs…
There
was
no
impa…
expe…
for
the
three
mont…
ended
Sept…
30,
2025.
Adjusted EBITDA is reconciled as follows:
Thr… Nine
Mon… Mont…
End… Ended
(d… Sep… Sept…
in 30, 30,
th… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
in… $ (8,0… ) $ 3,7… $ 39,… $ 10,0…
(l…
Le…
Net
lo…
at… — — — (254 )
to
no…
in…
Ad…
Inte… 4,280 3,9… 12,… 11,8…
expe…
Depr…
and 8,115 7,9… 23,… 22,6…
amor…
Inco…
tax (22 ) 2 1,2… 3,247
expe…
Equi… 17,4… 16,… 49,… 48,9…
comp…
Liti… — 546 481 1,608
cost…
Gain
on
sale
of — — (1 ) (72 )
prop…
and
equi…
Ad… $ 21,8… $ 32,… $ 127… $ 98,5…
EB…
Adju…
EBIT…
is a
non-…
fina…
meas…
that
is
pres…
as
supp…
disc…
that
we
defi…
as
net
inco…
(los…
befo…
inte…
(1) expe…
inco…
taxe…
depr…
and
amor…
expe…
cert…
liti…
cost…
gains
or
loss…
on
sale
of
prop…
and
equi…
and
equi…
comp…
expe…
Amor…
expe…
for
the
nine
mont…
ended
Sept…
30,
2025
incl…
$0.6
mill…
in
impa…
expe…
rela…
to
the
reme…
(2) of
good…
asso…
with
one
of
our
subs…
There
was
no
impa…
expe…
for
the
three
mont…
ended
Sept…
30,
2025.
Repr…
equi…
comp…
rela…
to
(3) gran…
made
in
the
appl…
year.
Repr…
liti…
costs
cons…
outs…
of
the
ordi…
cour…
of
busi…
based
on
the
foll…
cons…
which
we
asse…
regu…
(i)
the
freq…
of
simi…
cases
that
have
been
brou…
to
date,
or
(4) are
expe…
to be
brou…
with…
two
year…
(ii)
comp…
of
the
case,
(iii)
natu…
of
the
reme…
soug…
(iv)
liti…
post…
of
the
Comp…
(v)
coun…
invo…
and
(vi)
the
Comp…
over…
liti…
stra…
Conference Call Details
The company will host a conference call at 5 p.m. EDT today to discuss these
results and management’s outlook for future financial and operational
performance. A live audio webcast will be available online at
https://ir.alignmenthealth.com/. At the start of the conference call,
participants may access the webcast at the following link: . A replay of the
call will be available via webcast for on-demand listening shortly after the
completion of the call, at the same web links, and will remain available for
approximately 12 months.
About Alignment Health
Alignment Health is championing a new path in senior care that empowers members
to age well and live their most vibrant lives. A consumer brand name of
Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team
makes high-quality, low-cost care a reality for its Medicare Advantage members
every day. Based in California, the company partners with nationally recognized
and trusted local providers to deliver coordinated care, powered by its
customized care model, 24/7 concierge care team and purpose-built technology,
AVA. As it expands its offerings and grows its national footprint, Alignment
upholds its core values of leading with a serving heart and putting the senior
first. For more information, visit .
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995, as amended. These forward-looking statements include statements
regarding our future growth and our financial outlook for the quarter and year
ending Dec. 31, 2026. Forward-looking statements are subject to risks and
uncertainties and are based on assumptions that may prove to be inaccurate,
which could cause actual results to differ materially from those expected or
implied by the forward-looking statements. Actual results may differ materially
from the results predicted, and reported results should not be considered as an
indication of future performance. Important risks and uncertainties that could
cause our actual results and financial condition to differ materially from those
indicated in the forward-looking statements include, among others, the
following: our ability to successfully execute our business plan and achieve
anticipated operational improvements and financial results; our ability to
manage changes in medical costs and healthcare utilization, and our ability to
accurately estimate, price for and manage such costs and utilization; our
ability to attract new members and enter new markets, including the need for
certain governmental approvals; our ability to achieve and maintain a high
rating for our plans on the Five Star Quality Rating System; our ability to
develop and maintain satisfactory relationships with care providers that service
our members; risks associated with being a government contractor, including
potential federal reductions in MA funding; changes in laws and regulations
applicable to our business model; risks related to our indebtedness; changes in
market or industry conditions and receptivity to our technology and services;
results of litigation or a security incident; and the impact of shortages of
qualified personnel and related increases in our labor costs. For a detailed
discussion of the risk factors that could affect our actual results, please
refer to the risk factors identified in our Annual Report on Form 10-K for the
year ended Dec. 31, 2025, our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2026 and the other periodic reports we file with the SEC.
All information provided in this release and in the attachments is as of the
date hereof, and we undertake no duty to update or revise this information
unless required by law.
Condensed Consolidated Balance
Sheets
(in thousands, except par value
and share amounts) September 30, December 31,
(Unaudited) 2026 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current Assets:
Cash and cash equivalents $ 727,694 $ 575,817
Accounts receivable (less
allowance for credit losses of 242,545 253,207
$699 at September 30, 2026 and
$833 at December 31, 2025)
Investments - current 15,260 28,413
Prepaid expenses and other
current 192,808 94,140
assets
Total current assets 1,178,307 951,577
Property and equipment, net 66,439 64,251
Right of use asset, net 7,206 7,019
Goodwill 32,060 32,060
Intangible assets, net 4,550 4,550
Other assets 8,301 6,329
Total assets $ 1,296,863 $ 1,065,786
Liabilities and Stockholders'
Equity
Current Liabilities:
Medical expenses payable $ 621,746 $ 474,569
Accounts payable and accrued 34,562 33,284
expenses
Accrued compensation 32,744 49,013
Total current liabilities 689,052 556,866
Long-term debt, net of debt
issuance 324,497 323,176
costs
Long-term portion of lease 6,202 6,467
liabilities
Total liabilities 1,019,751 886,509
Stockholders' Equity:
Preferred stock, $0.001 par
value; 100,000,000 shares
authorized as of
September 30, 2026 and December — —
31, 2025, respectively; no shares
issued and
outstanding as of September 30,
2026 and December 31, 2025
Common stock, $0.001 par value;
1,000,000,000 shares authorized
as of
September 30, 2026 and December
31, 2025; 209,152,387 and 209 205
204,153,619 shares
issued and outstanding as of
September 30, 2026 and December
31, 2025,
respectively
Additional paid-in capital 1,245,996 1,188,089
Accumulated deficit (969,093 ) (1,009,017 )
Total stockholders' equity 277,112 179,277
Total liabilities and
stockholders' $ 1,296,863 $ 1,065,786
equity
Con…
Con…
Sta…
of
Ope…
(in
tho…
exc… Three Nine
per Mont… Months
sha… Ended Ended
amo… Sept… Septe…
(Un… 30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Ear… $ 1,348… $ 983,… $ 3,90… $ 2,907…
pre…
Oth… 10,034 10,0… 27,6… 27,988
Tot… 1,358… 993,… 3,92… 2,935…
rev…
Exp…
Med… 1,217… 868,… 3,46… 2,570…
exp…
Sel…
gen…
and 136,3… 110,… 388,… 317,6…
adm…
exp…
Dep…
and 8,108 7,977 23,8… 22,574
amo…
Tot… 1,362… 986,… 3,87… 2,910…
exp…
Inc…
(lo… (3,794 ) 7,681 53,8… 25,036
from
ope…
Oth…
exp…
Int… 4,280 3,950 12,6… 11,850
exp…
Oth…
inc… — — (1 ) (89 )
net
Tot…
oth… 4,280 3,950 12,6… 11,761
exp…
Inc…
(lo…
bef… (8,074 ) 3,731 41,1… 13,275
inc…
tax…
Pro…
(be…
for (22 ) 2 1,269 3,247
inc…
tax…
Net
inc… $ (8,052 ) $ 3,729 $ 39,9… $ 10,028
(lo…
Les…
Net
loss
att… — — — (254 )
to
non…
int…
Net
inc…
(lo…
att… $ (8,052 ) $ 3,729 $ 39,9… $ 10,282
to
Ali…
Hea…
Inc.
Net
inc…
(lo…
per
sha…
att…
to
Ali…
Hea…
Inc…
Bas… (0.04 ) 0.02 0.19 0.05
Dil… (0.04 ) 0.02 0.19 0.05
Wei…
com…
sha…
out…
Bas… 208,5… 199,… 207,… 197,0…
Dil… 208,5… 208,… 214,… 208,4…
Condensed
Consolidated
Statements of Cash
Flows
(in thousands)
(Unaudited) Nine Months Ended
Operating September 30,
Activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 39,924 $ 10,028
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Provision for credit 699 548
loss
Gain on sale of
property and (1 ) (72 )
equipment
Depreciation and 23,834 22,648
amortization
Amortization-invest… (478 ) (1,041 )
discount
Amortization-debt 1,790 1,321
issuance costs
Equity-based 49,680 48,967
compensation
Non-cash lease 1,439 1,178
expense
Changes in operating
assets and
liabilities:
Accounts receivable 9,963 (66,451 )
Prepaid expenses and
other current (98,668 ) (84,326 )
assets
Other assets (9 ) (47 )
Medical expenses 147,177 239,008
payable
Accounts payable and 1,004 11,185
accrued expenses
Accrued compensation (16,269 ) 8,349
Lease liabilities (1,690 ) (993 )
Net cash provided by
operating 158,395 190,302
activities
Investing
Activities:
Purchase of (32,510 ) (45,194 )
investments
Sale of property and — 75
equipment
Maturities of 46,135 57,995
investments
Sale of business — 1,065
Acquisition of
property and (25,952 ) (21,752 )
equipment
Net cash used in (12,327 ) (7,811 )
investing activities
Financing
Activities:
Debt issuance costs (2,397 ) (26 )
Proceeds from stock 8,231 2,771
option exercises
Net cash provided by
financing 5,834 2,745
activities
Net increase in cash 151,902 185,236
Cash, cash
equivalents and
restricted 577,937 434,942
cash at beginning of
period
Cash, cash
equivalents and
restricted $ 729,839 $ 620,178
cash at end of
period
Supplemental
disclosure of cash
flow
information:
Cash paid for $ 7,013 $ 6,740
interest
Supplemental
non-cash investing
and
financing
activities:
Acquisition of
property in accounts $ 9 $ 79
payable
The following table provides a reconciliation of cash, cash equivalents and
restricted cash reported within the consolidated balance sheets to the total
above:
September 30, September 30,
2026 2025
───────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 727,694 $ 618,067
Restricted cash in other assets 2,145 2,111
Total $ 729,839 $ 620,178
Non-GAAP Financial Measures
Certain of these financial measures are considered “non-GAAP” financial measures
within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We
believe that non-GAAP financial measures provide an additional way of viewing
aspects of our operations that, when viewed with the GAAP results, provide a
more complete understanding of our results of operations and the factors and
trends affecting our business. These non-GAAP financial measures are also used
by our management to evaluate financial results and to plan and forecast future
periods. However, non-GAAP financial measures should be considered as a
supplement to, and not as a substitute for, or superior to, the corresponding
measures calculated in accordance with GAAP. Non-GAAP financial measures used by
us may differ from the non-GAAP measures used by other companies, including our
competitors. To supplement our consolidated financial statements presented on a
GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio,
Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that
our management uses to assess our operating performance. Because these measures
facilitate internal comparisons of our historical operating performance on a
more consistent basis, we use these measures for business planning purposes and
in evaluating acquisition opportunities.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that we define as net income
(loss) before interest expense, income taxes, depreciation and amortization
expense, certain litigation costs, gains or losses on sale of property and
equipment, and equity-based compensation expense.
Adjusted EBITDA should not be considered in isolation of, or as an alternative
to, measures prepared in accordance with GAAP. There are a number of limitations
related to the use of Adjusted EBITDA in lieu of net income (loss), which is the
most directly comparable financial measure calculated in accordance with GAAP.
Our use of the term Adjusted EBITDA may vary from the use of similar terms by
other companies in our industry and accordingly may not be comparable to
similarly titled measures used by other companies.
Medical Benefits Ratio (MBR)
We calculate our MBR by dividing total medical expenses, excluding depreciation,
and medical equity-based compensation, by total revenues in a given period.
Adjusted Gross Profit
Adjusted gross profit is a non-GAAP financial measure that we define as income
(loss) from operations before depreciation and amortization, medical equity-
based compensation expense, and selling, general, and administrative expenses.
Adjusted gross profit should not be considered in isolation of, or as an
alternative to, measures prepared in accordance with GAAP. There are a number of
limitations related to the use of adjusted gross profit in lieu of income (loss)
from operations, which is the most directly comparable financial measure
calculated in accordance with GAAP.
Our use of the term adjusted gross profit may vary from the use of similar terms
by other companies in our industry and accordingly may not be comparable to
similarly titled measures used by other companies.
Investor Contact
Harrison Zhuo
Media Contact
Jerry Slowey
[email protected]